Back

Lp(a) testing and LDL-C levels among australian ASCVD patients in 2022: a cross-sectional study from the advara heartcare network (PREVAIL)

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lp(a) and apoproteins as risk factors Biomarkers ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Ravi SANTANI

Sydney (Australia)

7 More presentations in this session

Presentation thumbnail
Does the LPA genotype have a role in coronary artery disease risk beyond Lp(a) values?
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Comparison of Lp(a) assessment in patients with atherosclerotic cardiovascular disease between office-based cardiologists and general practitioners
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Causal associations of insulin and Lp(a) levels: a Mendelian randomization study
Associate Professor T. Osadnik (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
A retrospective analysis of patients with very HIGH level of LDL-C and the predictors of mortality (HIGH-LDL-PM Registry)
Associate Professor U. Sinan (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
The prevalence, patients characteristics and risk factors of hyper-Lp(a)-emia in the Polish population. The first results from the PMMHRI-Lp(a) Registry
Professor M. Banach (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Lp(a) and apoproteins as risk factors

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record database
thumbnail
Congress Presentation
A systematic review of lipoprotein(a) reporting in Australia: variability in availability, measurement, and clinical recommendations
thumbnail
Congress Presentation
LDL-C target attainment and statin use in patients with ASCVD, familial hypercholesterolaemia, and those otherwise at moderate/high-risk of ASCVD in australian general practice (SCOPE-GP)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources